BPC-157 + TB-500 Stack: Dosage, Evidence & Risks
This is the most commonly discussed combination in the research-peptide recovery community. Here’s what’s actually behind the pairing, what’s never been studied, and a calculator for both peptides at once.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Photo: Julia Taubitz / UnsplashThe rationale people give for stacking these two isn’t crazy, it’s just untested. BPC-157’s animal evidence leans toward localized tissue repair (tendon, ligament, gut lining). TB-500 is sold as a fragment of thymosin beta-4, a protein whose animal and cell-culture evidence leans toward systemic effects like cell migration and new blood vessel formation. The idea is that one handles the local injury site while the other supports repair more broadly.
That’s a mechanistic story built by combining two separate bodies of animal research. No published study, in animals or humans, has tested BPC-157 and TB-500 given together. Whatever happens when you combine two under-studied compounds hasn’t been measured, it’s an assumption layered on top of two already-thin evidence bases.
Both peptides, one calculation.
Reconstitute and dose each peptide independently, then see the combined draw volume if injecting them together.
Everything cited above, from both peptides.
Stack questions, answered.
Nobody has published a study that tests the two together, in humans or animals. Each has separate (mostly animal-level) evidence on its own. Stacking them means combining two individually under-studied compounds, not adding a known quantity to another known quantity. Any claim that the combination is "safe" is an assumption, not a finding.
The rationale in the biohacking and research-peptide community is that BPC-157 is more associated with localized tissue (tendon, ligament, gut) repair, while TB-500 is described as acting more systemically on cell migration and angiogenesis. The theory is that the two are complementary. That's a mechanistic hypothesis based on separate animal studies of each compound, not a tested claim about the pair.
Anecdotal and vendor-reported protocols most often describe BPC-157 at 250-500 mcg/day alongside TB-500 at 2-2.5mg twice weekly, run for 8-12 weeks with a break afterward. This is what shows up most often in self-reported sources, not a validated or recommended protocol.
People commonly do, if both are reconstituted in the same diluent (bacteriostatic water) and the total volume stays reasonable for a single subcutaneous injection. The stack-mode calculator above adds up the two draw volumes so you can see the combined total, it doesn't verify chemical compatibility between the two solutions.
Look at each peptide individually.
Combining compounds you can't fully verify is exactly the risk PepGuard exists to catch.
Create your account to check any peptide, or any combination, against the actual research before it goes anywhere near your body.